A Real-world Study on the Incidence and Outcome of Immune-related Adverse Events in Lung Cancer Patients
Background and objective Immune-related adverse events (irAEs) are commonly occurred in patients treated with immune checkpoint inhibitors. However, evidence of irAEs derived from the Chinese population is relatively lacking. The aim of this study was to investigate the incidence and outcomes of irA...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Chinese Anti-Cancer Association; Chinese Antituberculosis Association
2023-04-01
|
| Series: | Chinese Journal of Lung Cancer |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.3779/j.issn.1009-3419.2023.101.08 |
| _version_ | 1797826797485686784 |
|---|---|
| author | Shaohua CUI Xiaoxiao GE Xiangyang LI |
| author_facet | Shaohua CUI Xiaoxiao GE Xiangyang LI |
| author_sort | Shaohua CUI |
| collection | DOAJ |
| description | Background and objective Immune-related adverse events (irAEs) are commonly occurred in patients treated with immune checkpoint inhibitors. However, evidence of irAEs derived from the Chinese population is relatively lacking. The aim of this study was to investigate the incidence and outcomes of irAEs in Chinese patients with lung cancer after receiving immune checkpoint inhibitors (ICIs). Methods Clinical and follow-up data from lung cancer patients who received at least one time of ICIs from January 2018 to September 2021 at Huadong Hospital, Fudan University were included. Statistical descriptions and Kaplan-Meier method were used to analyze the overall incidence of irAEs, as well as the incidence and outcomes of each type of irAEs. Results 135 patients were included in the study. 106 patients (78.5%) presented at least one type of irAEs, and the median time to first irAEs onset was 28 d. Most irAEs occurred at early time after treatment, and most irAEs were mild-moderate and reversible. 57 patients (42.2%) died at the study cutoff. The mortality rate of severe irAEs was 12.6% (n=17), and among them 7 patients (41.2%) died of pneumonitis. The median progression-free survival (PFS) and overall survival (OS) time of the total population was 505 d (95%CI: 352-658) and 625 d (95%CI: 491-759), respectively. Patients who presented any irAEs achieved a longer PFS than those who did not (median PFS: 533 d vs 179 d, P=0.037, HR=0.57), while patients who presented skin toxicities achieved a longer OS than patients who did not (median OS: 797 d vs 469 d, P=0.006, HR=0.70). Conclusion In real-world settings, irAEs in lung cancer patients were commonly observed, with pneumonitis as the most common fatal irAEs. In addition, patients who presented any irAEs may tend to achieve a longer PFS. |
| first_indexed | 2024-04-09T12:37:58Z |
| format | Article |
| id | doaj.art-c777795dc56141a380fe06eb87e783fa |
| institution | Directory Open Access Journal |
| issn | 1009-3419 1999-6187 |
| language | zho |
| last_indexed | 2024-04-09T12:37:58Z |
| publishDate | 2023-04-01 |
| publisher | Chinese Anti-Cancer Association; Chinese Antituberculosis Association |
| record_format | Article |
| series | Chinese Journal of Lung Cancer |
| spelling | doaj.art-c777795dc56141a380fe06eb87e783fa2023-05-15T07:44:48ZzhoChinese Anti-Cancer Association; Chinese Antituberculosis AssociationChinese Journal of Lung Cancer1009-34191999-61872023-04-0126425726410.3779/j.issn.1009-3419.2023.101.08A Real-world Study on the Incidence and Outcome of Immune-related Adverse Events in Lung Cancer PatientsShaohua CUI0Xiaoxiao GE1Xiangyang LI2Department of Respiratory and Critical Care Medicine, Huadong Hospital, Fudan University, Shanghai 200040, ChinaDepartment of Respiratory and Critical Care Medicine, Huadong Hospital, Fudan University, Shanghai 200040, ChinaDepartment of Respiratory and Critical Care Medicine, Huadong Hospital, Fudan University, Shanghai 200040, ChinaBackground and objective Immune-related adverse events (irAEs) are commonly occurred in patients treated with immune checkpoint inhibitors. However, evidence of irAEs derived from the Chinese population is relatively lacking. The aim of this study was to investigate the incidence and outcomes of irAEs in Chinese patients with lung cancer after receiving immune checkpoint inhibitors (ICIs). Methods Clinical and follow-up data from lung cancer patients who received at least one time of ICIs from January 2018 to September 2021 at Huadong Hospital, Fudan University were included. Statistical descriptions and Kaplan-Meier method were used to analyze the overall incidence of irAEs, as well as the incidence and outcomes of each type of irAEs. Results 135 patients were included in the study. 106 patients (78.5%) presented at least one type of irAEs, and the median time to first irAEs onset was 28 d. Most irAEs occurred at early time after treatment, and most irAEs were mild-moderate and reversible. 57 patients (42.2%) died at the study cutoff. The mortality rate of severe irAEs was 12.6% (n=17), and among them 7 patients (41.2%) died of pneumonitis. The median progression-free survival (PFS) and overall survival (OS) time of the total population was 505 d (95%CI: 352-658) and 625 d (95%CI: 491-759), respectively. Patients who presented any irAEs achieved a longer PFS than those who did not (median PFS: 533 d vs 179 d, P=0.037, HR=0.57), while patients who presented skin toxicities achieved a longer OS than patients who did not (median OS: 797 d vs 469 d, P=0.006, HR=0.70). Conclusion In real-world settings, irAEs in lung cancer patients were commonly observed, with pneumonitis as the most common fatal irAEs. In addition, patients who presented any irAEs may tend to achieve a longer PFS.http://dx.doi.org/10.3779/j.issn.1009-3419.2023.101.08lung neoplasmsimmune-related adverse eventsimmunotherapysurvival time |
| spellingShingle | Shaohua CUI Xiaoxiao GE Xiangyang LI A Real-world Study on the Incidence and Outcome of Immune-related Adverse Events in Lung Cancer Patients Chinese Journal of Lung Cancer lung neoplasms immune-related adverse events immunotherapy survival time |
| title | A Real-world Study on the Incidence and Outcome of Immune-related Adverse Events in Lung Cancer Patients |
| title_full | A Real-world Study on the Incidence and Outcome of Immune-related Adverse Events in Lung Cancer Patients |
| title_fullStr | A Real-world Study on the Incidence and Outcome of Immune-related Adverse Events in Lung Cancer Patients |
| title_full_unstemmed | A Real-world Study on the Incidence and Outcome of Immune-related Adverse Events in Lung Cancer Patients |
| title_short | A Real-world Study on the Incidence and Outcome of Immune-related Adverse Events in Lung Cancer Patients |
| title_sort | real world study on the incidence and outcome of immune related adverse events in lung cancer patients |
| topic | lung neoplasms immune-related adverse events immunotherapy survival time |
| url | http://dx.doi.org/10.3779/j.issn.1009-3419.2023.101.08 |
| work_keys_str_mv | AT shaohuacui arealworldstudyontheincidenceandoutcomeofimmunerelatedadverseeventsinlungcancerpatients AT xiaoxiaoge arealworldstudyontheincidenceandoutcomeofimmunerelatedadverseeventsinlungcancerpatients AT xiangyangli arealworldstudyontheincidenceandoutcomeofimmunerelatedadverseeventsinlungcancerpatients AT shaohuacui realworldstudyontheincidenceandoutcomeofimmunerelatedadverseeventsinlungcancerpatients AT xiaoxiaoge realworldstudyontheincidenceandoutcomeofimmunerelatedadverseeventsinlungcancerpatients AT xiangyangli realworldstudyontheincidenceandoutcomeofimmunerelatedadverseeventsinlungcancerpatients |